Non-steroidal anti-inflammatory drugs and cognitive function: Are prostaglandins at the heart of cognitive impairment in dementia and delirium?

Journal of Neuroimmune Pharmacology

Volumn 7, Issue 1, 2012, Pages 60-73

  Cunningham, Colm ^a   Skelly, Donal Thomas ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Alzheimer's disease; Cyclooxygenase; Delirium; Dementia; Learning; Memory; Microglia; Prostaglandin

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETYLSALICYLIC ACID; AMYLOID BETA PROTEIN; CELECOXIB; DICLOFENAC; IBUPROFEN; INDOMETACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PROSTANOID RECEPTOR; SULINDAC SULFIDE; TRIFLUSAL;

COGNITIVE DEFECT; DELIRIUM; DEMENTIA; DISEASE EXACERBATION; ENZYME INHIBITION; EXPERIMENTAL MODEL; HUMAN; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REVIEW; SYNAPSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COGNITION; COGNITION DISORDERS; DELIRIUM; DEMENTIA; HUMANS; PROSTAGLANDINS;

EID: 81755181762     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-011-9312-5     Document Type: Review

References (151)

1. Ahmad AS, Saleem S, Ahmad M, Dore S (2006a) Prostaglandin EP1 receptor contributes to excitotoxicity and focal ischemic brain damage. Toxicol Sci 89:265-270 (Pubitemid 43013774)
2. Ahmad AS, Zhuang H, Echeverria V, Dore S (2006b) Stimulation of prostaglandin EP2 receptors prevents NMDA-induced excitotoxicity. J Neurotrauma 23:1895-1903 (Pubitemid 46034458)
3. Aisen PS, Schmeidler J, Pasinetti GM (2002) Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology 58:1050-1054 (Pubitemid 34298544)
4. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ (2003) Effects of rofecoxib or naproxen vs. placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289:2819-2826 (Pubitemid 37430117)
5. Aisen PS, Thal LJ, Ferris SH, Assaid C, Nessly ML, Giuliani MJ, Lines CR, Norman BA, Potter WZ (2008) Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial. Curr Alzheimer Res 5:73-82 (Pubitemid 351536357)
6. Andreasson K (2010) Emerging roles of PGE2 receptors in models of neurological disease. Prostag Other Lipid Mediat 91:104-112
7. Andreasson KI, Savonenko A, Vidensky S, Goellner JJ, Zhang Y, Shaffer A, Kaufmann WE, Worley PF, Isakson P, Markowska AL (2001) Age-dependent cognitive deficits and neuronal apoptosis in cyclooxygenase-2 transgenic mice. J Neurosci. 21(20):8198-8209 (Pubitemid 32952775)
8. APA (1994) Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). American Psychiatry Association, Washington
9. Ashe KH, Zahs KR (2010) Probing the biology of Alzheimer's disease in mice. Neuron 66:631-645
10. Bannerman DM, Yee BK, Good MA, Heupel MJ, Iversen SD, Rawlins JN (1999) Double dissociation of function within the hippocampus: a comparison of dorsal, ventral, and complete hippocampal cytotoxic lesions. Behav Neurosci 113:1170-1188 (Pubitemid 30013825)
11. Bannerman DM, Deacon RM, Offen S, Friswell J, GrubbM, Rawlins JN (2002) Double dissociation of function within the hippocampus: spatial memory and hyponeophagia. Behav Neurosci 116:884-901
12. Barnes P, Hale G, Good M (2004) Intramaze and extramaze cue processing in adult APPSWE Tg2576 transgenic mice. Behav Neurosci 118:1184-1195 (Pubitemid 39578466)
13. Barrientos RM, Frank MG, Hein AM, Higgins EA, Watkins LR, Rudy JW, Maier SF (2009) Time course of hippocampal IL-1 beta and memory consolidation impairments in aging rats following peripheral infection. Brain Behav Immun 23:46-54
14. Beloosesky Y, Hendel D, Weiss A, Hershkovitz A, Grinblat J, Pirotsky A, Barak V (2007) Cytokines and C-reactive protein production in hip-fracture-operated elderly patients. J Gerontol A Biol Sci Med Sci 62:420-426 (Pubitemid 47065711)
15. Blais V, Turrin NP, Rivest S (2005) Cyclooxygenase 2 (COX-2) inhibition increases the inflammatory response in the brain during systemic immune stimuli. J Neurochem 95:1563-1574 (Pubitemid 41804054)
16. Bosetti F (2007) Arachidonic acid metabolism in brain physiology and pathology: lessons from genetically altered mouse models. J Neurochem 102:577-586 (Pubitemid 47057279)
17. Breitner JC, Baker LD, Montine TJ, Meinert CL, Lyketsos CG, Ashe KH, Brandt J, Craft S, Evans DE, Green RC, Ismail MS, Martin BK, Mullan MJ, Sabbagh M, Tariot PN (2011) Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement 7:402-411
18. Breteler MM (2000) Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging 21:153-160 (Pubitemid 30387074)
19. Brugg B, Dubreuil YL, Huber G, Wollman EE, Delhaye-Bouchaud N, Mariani J (1995) Inflammatory processes induce beta-amyloid precursor protein changes in mouse brain. Proc Natl Acad Sci U S A 92:3032-3035
20. Burns A, Gallagley A, Byrne J (2004) Delirium. J Neurol Neurosurg Psychiatr 75:362-367 (Pubitemid 38338762)
21. Caccamo A, Oddo S, Tran LX, Laferla FM (2007) Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am J Pathol 170:1669-1675 (Pubitemid 47339311)
22. Cacucci F, Yi M, Wills TJ, Chapman P, O'keefe J (2008) Place cell firing correlates with memory deficits and amyloid plaque burden in Tg2576 Alzheimer mouse model. Proc Natl Acad Sci U S A 105:7863-7868 (Pubitemid 351872729)
23. Chapman PF, White GL, Jones MW, Cooper-Blacketer D, Marshall VJ, Irizarry M, Younkin L, Good MA, Bliss TV, Hyman BT, Younkin SG, Hsiao KK (1999) Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci 2:271-276 (Pubitemid 30491299)
24. Chen C, Bazan NG (2005) Endogenous PGE2 regulates membrane excitability and synaptic transmission in hippocampal CA1 pyramidal neurons. J Neurophysiol 93:929-941
25. Chen J, Buchanan JB, Sparkman NL, Godbout JP, Freund GG, Johnson RW (2008) Neuroinflammation and disruption in working memory in aged mice after acute stimulation of the peripheral innate immune system. Brain Behav Immun 22:301-311 (Pubitemid 351172703)
26. Choi SH, Bosetti F (2009) Cyclooxygenase-1 null mice show reduced neuroinflammation in response to beta-amyloid. Aging 1:234-244
27. Choi SH, Langenbach R, Bosetti F (2008) Genetic deletion or pharmacological inhibition of cyclooxygenase-1 attenuate lipopolysaccharide- induced inflammatory response and brain injury. FASEB J 22:1491-1501 (Pubitemid 351656789)
28. Choi SH, Aid S, Bosetti F (2009) The distinct roles of cyclooxygenase-1 and -2 in neuroinflammation: implications for translational research. Trends Pharmacol Sci 30:174-181
29. Cibelli M, Fidalgo AR, Terrando N, Ma D, Monaco C, Feldmann M, Takata M, Lever IJ, Nanchahal J, Fanselow MS, Maze M (2010) Role of interleukin-1beta in postoperative cognitive dysfunction. Ann Neurol 68:360-368
30. Coma M, Sereno L, Da Rocha-Souto B, Scotton TC, Espana J, Sanchez MB, Rodriguez M, Agullo J, Guardia-Laguarta C, Garcia-Alloza M, Borrelli LA, Clarimon J, Lleo A, Bacskai BJ, Saura CA, Hyman BT, Gomez-Isla T (2010) Triflusal reduces dense-core plaque load, associated axonal alterations and inflammatory changes, and rescues cognition in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 38:482-491
31. Combrinck M, Williams J, De Berardinis MA, Warden D, Puopolo M, Smith AD, Minghetti L (2006) Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease. J Neurol Neurosurg Psychiatr 77:85-88 (Pubitemid 43022699)
32. Combs CK, Johnson DE, Karlo JC, Cannady SB, Landreth GE (2000) Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci 20:558-567 (Pubitemid 30225558)
33. Corcoran KA, Lu Y, Turner RS, Maren S (2002) Overexpression of hAPPswe impairs rewarded alternation and contextual fear conditioning in a transgenic mouse model of Alzheimer's disease. Learn Mem 9:243-252
34. Cowley TR, Fahey B, O'mara SM (2008) COX-2, but not COX-1, activity is necessary for the induction of perforant path long-term potentiation and spatial learning in vivo. Eur J Neurosci 27:2999-3008 (Pubitemid 351832213)
35. Cunningham C (2011) Systemic inflammation and delirium: important co-factors in the progression of dementia. Biochem Soc Trans 39 (4):945-953
36. Cunningham C, Sanderson DJ (2008) Malaise in the water maze: untangling the effects of LPS and IL-1beta on learning and memory. Brain Behav Immun 22:1117-1127
37. Cunningham C, Deacon R, Wells H, Boche D, Waters S, Diniz CP, Scott H, Rawlins JN, Perry VH (2003) Synaptic changes characterize early behavioural signs in the ME7 model of murine prion disease. Eur J Neurosci 17:2147-2155 (Pubitemid 36713975)
38. Cunningham C, Wilcockson DC, Campion S, Lunnon K, Perry VH (2005) Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J Neurosci 25:9275-9284 (Pubitemid 41500836)
39. Cunningham C, Campion S, Lunnon K, Murray CL, Woods JF, Deacon RM, Rawlins JN, Perry VH (2009) Systemic inflammation induces acute behavioral and cognitive changes and accelerates neurodegenerative disease. Biol Psychiatr 65:304-312
40. Davies P, Maloney AJ (1976) Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2:1403 (Pubitemid 8004505)
41. De La Torre JC (2004) Is Alzheimer's disease a neurodegenerative or a vascular disorder? data, dogma, and dialectics. Lancet Neurol 3:184-190 (Pubitemid 38232669)
42. Deininger MH, Bekure-Nemariam K, Trautmann K, Morgalla M, Meyermann R, Schluesener HJ (2003) Cyclooxygenase-1 and -2 in brains of patients who died with sporadic Creutzfeldt-Jakob disease. J Mol Neurosci 20:25-30 (Pubitemid 36399464)
43. Dodart JC, Bales KR, Gannon KS, Greene SJ, Demattos RB, Mathis C, Delong CA, Wu S, Wu X, Holtzman DM, Paul SM (2002) Immunization reverses memory deficits without reducing brain abeta burden in Alzheimer's disease model. Nat Neurosci 5:452-457 (Pubitemid 34454251)
44. Ek M, Engblom D, Saha S, Blomqvist A, Jakobsson PJ, Ericsson-Dahlstrand A (2001) Inflammatory response: pathway across the blood-brain barrier. Nature 410:430-431 (Pubitemid 32240034)
45. Etminan M, Gill S, Samii A (2003) Effect of non-steroidal antiinflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 327:128
46. Fick DM, Agostini JV, Inouye SK (2002) Delirium superimposed on dementia: a systematic review. J Am Geriatr Soc 50:1723-1732 (Pubitemid 35192547)
47. Field R, Campion S, Warren C, Murray C, Cunningham C (2010) Systemic challenge with the TLR3 agonist poly I:C induces amplified IFNalpha/beta and IL-1beta responses in the diseased brain and exacerbates chronic neurodegeneration. Brain Behav Immun 24:996-1007
48. Filali M, Lalonde R (2009) Age-related cognitive decline and nesting behavior in an APPswe/PS1 bigenic model of Alzheimer's disease. Brain Res 1292:93-99
49. Fong TG, Jones RN, Shi P, Marcantonio ER, Yap L, Rudolph JL, Yang FM, Kiely DK, Inouye SK (2009) Delirium accelerates cognitive decline in Alzheimer disease. Neurology 72:1570-1575
50. Frank MG, Barrientos RM, Hein AM, Biedenkapp JC, Watkins LR, Maier SF (2010) IL-1RA blocks E. coli-induced suppression of Arc and long-term memory in aged F344xBN F1 rats. Brain Behav Immun 24:254-262
51. Frye CA, Walf AA (2008) Effects of progesterone administration and APPswe+PSEN1Deltae9 mutation for cognitive performance of mid-aged mice. Neurobiol Learn Mem 89:17-26 (Pubitemid 350102253)
52. Garcia-Bueno B, Serrats J, Sawchenko PE (2009) Cerebrovascular cyclooxygenase-1 expression, regulation, and role in hypothalamicpituitary- adrenal axis activation by inflammatory stimuli. J Neurosci 29:12970-12981
53. Glazner KaC, Odero GL, Anema E, Motnenko A, Schapansky J, Grossman D, Oliver DR, Glazner GW, Albensi BC (2010) Strain specific differences in memory and neuropathology in a mouse model of Alzheimer's disease. Life Sci 86:942-950
54. Godbout JP, Chen J, Abraham J, Richwine AF, Berg BM, Kelley KW, Johnson RW (2005) Exaggerated neuroinflammation and sickness behavior in aged mice following activation of the peripheral innate immune system. FASEB J 19:1329-1331 (Pubitemid 41113739)
55. Gomez-Isla T, Blesa R, Boada M, Clarimon J, Del Ser T, Domenech G, Ferro JM, Gomez-Anson B, Manubens JM, Martinez-Lage JM, Munoz D, Pena-Casanova J, Torres F (2008) A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: the TRIMCI study. Alzheimer Dis Assoc Disord 22:21-29 (Pubitemid 351651394)
56. Good MA, Hale G (2007) The "Swedish" mutation of the amyloid precursor protein (APPswe) dissociates components of objectlocation memory in aged Tg2576 mice. Behav Neurosci 121:1180-1191
57. Griffin DE,Wesselingh SL,Mcarthur JC (1994) Elevated central nervous systemprostaglandins in human immunodeficiency virus-associated dementia. Ann Neurol 35:592-597
58. Guenther K, Deacon RM, Perry VH, Rawlins JN (2001) Early behavioural changes in scrapie-affected mice and the influence of dapsone. Eur J Neurosci 14:401-409 (Pubitemid 32777645)
59. Hauss-Wegrzyniak B, Dobrzanski P, Stoehr JD, Wenk GL (1998) Chronic neuroinflammation in rats reproduces components of the neurobiology of Alzheimer's disease. Brain Res 780:294-303 (Pubitemid 28082916)
60. Hein AM, O'banion MK (2009) Neuroinflammation and memory: the role of prostaglandins. Mol Neurobiol 40:15-32
61. Hein AM, Stutzman DL, Bland ST, Barrientos RM, Watkins LR, Rudy JW, Maier SF (2007) Prostaglandins are necessary and sufficient to induce contextual fear learning impairments after interleukin-1 beta injections into the dorsal hippocampus. Neuroscience 150:754-763 (Pubitemid 350235798)
62. Heneka MT, Sastre M, Dumitrescu-Ozimek L, Hanke A, Dewachter I, Kuiperi C, O'banion K, Klockgether T, Van Leuven F, Landreth GE (2005) Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain 128:1442-1453 (Pubitemid 40826196)
63. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA (2008) Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 372:216-223 (Pubitemid 351978111)
64. Holmes C, Cunningham C, Zotova E, Woolford J, Dean C, Kerr S, Culliford D, Perry VH (2009) Systemic inflammation and disease progression in Alzheimer disease. Neurology 73:768-774
65. Hoozemans JJ, Rozemuller AJ, Janssen I, De Groot CJ, Veerhuis R, Eikelenboom P (2001) Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol 101:2-8 (Pubitemid 32124493)
66. Huang ZL, Sato Y, Mochizuki T, Okada T, Qu WM, Yamatodani A, Urade Y, Hayaishi O (2003) Prostaglandin E2 activates the histaminergic system via the EP4 receptor to induce wakefulness in rats. J Neurosci 23:5975-5983 (Pubitemid 36859436)
67. Hyman BT, Van Hoesen GW, Damasio AR, Barnes CL (1984) Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 225:1168-1170 (Pubitemid 14029099)
68. Iadecola C, Niwa K, Nogawa S, Zhao X, Nagayama M, Araki E, Morham S, Ross ME (2001) Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci U S A 98:1294-1299 (Pubitemid 32121226)
69. In 'T Veld BA, Ruitenberg A, Hofman A, Launer LJ, Van Duijn CM, Stijnen T, Breteler MMB, Stricker BHC (2001) Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. New Engl J Med 345:1515-1521 (Pubitemid 33144916)
70. Inouye SK, Van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI (1990) Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med 113:941-948
71. Iordanova MD, Burnett DJ, Aggleton JP, Good M, Honey RC (2009) The role of the hippocampus in mnemonic integration and retrieval: complementary evidence from lesion and inactivation studies. Eur J Neurosci 30:2177-2189
72. Kawano T, Anrather J, Zhou P, Park L, Wang G, Frys KA, Kunz A, Cho S, Orio M, Iadecola C (2006) Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat Med 12:225-229 (Pubitemid 43214750)
73. King DL, Arendash GW (2002) Behavioral characterization of the Tg2576 transgenic model of Alzheimer's disease through 19 months. Physiol Behav 75:627-642 (Pubitemid 34521825)
74. Kitaoka S, Furuyashiki T, Nishi A, Shuto T, Koyasu S, Matsuoka T, Miyasaka M, Greengard P, Narumiya S (2007) Prostaglandin E2 acts on EP1 receptor and amplifies both dopamine D1 and D2 receptor signaling in the striatum. J Neurosci 27:12900-12907 (Pubitemid 350159587)
75. Kitazawa M, Oddo S, Yamasaki TR, Green KN, Laferla FM (2005) Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci 25:8843-8853 (Pubitemid 41384452)
76. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A (2001) Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 322:1447-1451 (Pubitemid 32575406)
77. Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, Younkin S, Ashe KH (2002) Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 22:6331-6335 (Pubitemid 35386387)
78. Kotilinek LA, Westerman MA, Wang Q, Panizzon K, Lim GP, Simonyi A, Lesne S, Falinska A, Younkin LH, Younkin SG, Rowan M, Cleary J,Wallis RA, Sun GY, Cole G, Frautschy S, Anwyl R, Ashe KH (2008) Cyclooxygenase-2 inhibition improves amyloid-betamediated suppression of memory and synaptic plasticity. Brain 131:651-664 (Pubitemid 351294724)
79. Kukar T, Prescott S, Eriksen JL, Holloway V, Murphy MP, Koo EH, Golde TE, Nicolle MM (2007) Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci 8:54
80. Landreth GE, Heneka MT (2001) Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease. Neurobiol Aging 22:937-944 (Pubitemid 34066562)
81. Landreth G, Jiang Q, Mandrekar S, Heneka M (2008) PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease. Neurotherapeutics 5:481-489 (Pubitemid 351952487)
82. Lazarus M, Yoshida K, Coppari R, Bass CE, Mochizuki T, Lowell BB, Saper CB (2007) EP3 prostaglandin receptors in the median preoptic nucleus are critical for fever responses. Nat Neurosci 10:1131-1133 (Pubitemid 47339949)
83. Lee DC, Rizer J, Selenica ML, Reid P, Kraft C, Johnson A, Blair L, Gordon MN, Dickey CA, Morgan D (2010) LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice. J Neuroinflamm 7:56
84. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA (1997) Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272:3406-3410
85. Leoutsakos JM, Muthen BO, Breitner JC, Lyketsos CG, For the ADAPT Research Team (2011) Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's disease anti-inflammatory prevention trial. Int J Geriatr Psychiatr. doi:10.1002/gps.2723
86. Liang X,Wang Q,Hand T,Wu L, Breyer RM, Montine TJ, AndreassonK (2005) Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. J Neurosci 25:10180-10187 (Pubitemid 41636214)
87. Lim GP, Yang F, Chu T, Chen P, Beech W, Teter B, Tran T, Ubeda O, Ashe KH, Frautschy SA, Cole GM (2000) Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 20:5709-5714 (Pubitemid 30636898)
88. Lim GP, Yang F, Chu T, Gahtan E, Ubeda O, Beech W, Overmier JB, Hsiao-Ashec K, Frautschy SA, Cole GM (2001) Ibuprofen effects on Alzheimer pathology and open field activity inAPPsw transgenic mice. Neurobiol Aging 22:983-991 (Pubitemid 34066567)
89. Liu D, Wu L, Breyer R, Mattson MP, Andreasson K (2005) Neuroprotection by the PGE2 EP2 receptor in permanent focal cerebral ischemia. Ann Neurol 57:758-761 (Pubitemid 40628868)
90. Lyketsos CG, Breitner JC, Green RC, Martin BK, Meinert C, Piantadosi S, SabbaghM(2007) Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 68:1800-1808 (Pubitemid 46791392)
91. Maclullich AM, Ferguson KJ, Miller T, De Rooij SE, Cunningham C (2008) Unravelling the pathophysiology of delirium: a focus on the role of aberrant stress responses. J Psychosom Res 65:229-238
92. Maclullich AM, Edelshain BT, Hall RJ, De Vries A, Howie SE, Pearson A, Middleton SD, Gillies F, Armstrong IR, White TO, Cunningham C, De Rooij SE, VanMunster BC (2011) Cerebrospinal fluid interleukin-8 levels are higher in people with hip fracture with perioperative delirium than in controls. J Am Geriatr Soc 59:1151-1153
93. Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, Evans D, Green R, Mullan M (2008) Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 65:896-905 (Pubitemid 352008472)
94. Matousek SB, Hein AM, Shaftel SS, Olschowka JA, Kyrkanides S, O'banion MK (2010) Cyclooxygenase-1 mediates prostaglandin E(2) elevation and contextual memory impairment in a model of sustained hippocampal interleukin-1beta expression. J Neurochem 114:247-258
95. Matsumoto Y, Yamaguchi T, Watanabe S, Yamamoto T (2004) Involvement of arachidonic acid cascade in working memory impairment induced by interleukin-1 beta. Neuropharmacology 46:1195-1200 (Pubitemid 38529943)
96. Matsuoka Y, Furuyashiki T, Bito H, Ushikubi F, Tanaka Y, Kobayashi T, Muro S, Satoh N, Kayahara T, Higashi M, Mizoguchi A, Shichi H, Fukuda Y, Nakao K, Narumiya S (2003) Impaired adrenocorticotropic hormone response to bacterial endotoxin in mice deficient in prostaglandin E receptor EP1 and EP3 subtypes. Proc Natl Acad Sci U S A 100:4132-4137 (Pubitemid 36418169)
97. Matsuoka Y, Furuyashiki T, Yamada K, Nagai T, Bito H, Tanaka Y, Kitaoka S, Ushikubi F, Nabeshima T, Narumiya S (2005) Prostaglandin E receptor EP1 controls impulsive behavior under stress. Proc Natl Acad Sci U S A 102:16066-16071 (Pubitemid 41552868)
98. Maubach KA, Davis RJ, Clark DE, Fenton G, Lockey PM, Clark KL, Oxford AW, Hagan RM, Routledge C, Coleman RA (2009) BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol 156:316-327
99. Mccullough L, Wu L, Haughey N, Liang X, Hand T, Wang Q, Breyer RM, Andreasson K (2004) Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci 24:257-268 (Pubitemid 38181690)
100. Mcgeer PL, Schulzer M, Mcgeer EG (1996) Arthritis and antiinflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47:425-432 (Pubitemid 26324038)
101. Mckee AC, Carreras I, Hossain L, Ryu H, Klein WL, Oddo S, Laferla FM, Jenkins BG, Kowall NW, Dedeoglu A (2008) Ibuprofen reduces A[beta], hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res 1207:225-236
102. Meagher D (2009) More attention, less confusion: time to lessen the burden of delirium. Int Rev Psychiatr 21:1-3
103. Melnikova T, Savonenko A, Wang Q, Liang X, Hand T, Wu L, Kaufmann WE, Vehmas A, Andreasson KI (2006) Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern. Neuroscience 141(3):1149-1162 (Pubitemid 44128685)
104. Mohri I, Kadoyama K, Kanekiyo T, Sato Y, Kagitani-Shimono K, Saito Y, Suzuki K, Kudo T, Takeda M, Urade Y, Murayama S, Taniike M (2007) Hematopoietic prostaglandin D synthase and DP1 receptor are selectively upregulated in microglia and astrocytes within senile plaques from human patients and in a mouse model of Alzheimer disease. J Neuropathol Exp Neurol 66:469-480 (Pubitemid 46869689)
105. Montine TJ, Sidell KR, Crews BC, Markesbery WR, Marnett LJ, Roberts LJ 2nd, Morrow JD (1999) Elevated CSF prostaglandin E2 levels in patients with probable AD. Neurology 53:1495-1498 (Pubitemid 29491943)
106. Morihara T, Teter B, Yang F, Lim GP, Boudinot S, Boudinot FD, Frautschy SA, Cole GM (2005) Ibuprofen suppresses interleukin- 1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid (abeta) pathology in Alzheimer's models. Neuropsychopharmacology 30:1111-1120 (Pubitemid 40720969)
107. Morris RGM, Garrud P, Rawlins JNP, O'keefe J (1982) Place navigation impaired in rats with hippocampal lesions. Nature 297:681-683 (Pubitemid 12096189)
108. Murray C, Sanderson DJ, Barkus C, Deacon RM, Rawlins JN, Bannerman DM, Cunningham C (2010) Systemic inflammation induces acute working memory deficits in the primed brain: relevance for delirium. Neurobiol Aging. doi:10.1016/j.neurobiolaging. 2010.04.002
109. Nguyen M, Camenisch T, Snouwaert JN, Hicks E, Coffman TM, Anderson PA, Malouf NN, Koller BH (1997) The prostaglandin receptor EP4 triggers remodelling of the cardiovascular system at birth. Nature 390:78-81 (Pubitemid 27494759)
110. Nguyen MD, D'aigle T, Gowing G, Julien JP, Rivest S (2004) Exacerbation of motor neuron disease by chronic stimulation of innate immunity in a mouse model of amyotrophic lateral sclerosis. J Neurosci 24:1340-1349 (Pubitemid 38222984)
111. Nogawa S, Zhang F, Ross ME, Iadecola C (1997) Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 17:2746-2755 (Pubitemid 27155008)
112. Perry VH (2010) Contribution of systemic inflammation to chronic neurodegeneration. Acta Neuropathol 120:277-286
113. Pott Godoy MC, Tarelli R, Ferrari CC, Sarchi MI, Pitossi FJ (2008) Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson's disease. Brain 131:1880-1894 (Pubitemid 351957456)
114. Quinn J, Montine T, Morrow J, Woodward WR, Kulhanek D, Eckenstein F (2003) Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease. J Neuroimmunol 137:32-41 (Pubitemid 36351563)
115. Rahkonen T, Luukkainen-Markkula R, Paanila S, Sivenius J, Sulkava R (2000) Delirium episode as a sign of undetected dementia among community dwelling elderly subjects: a 2 year follow up study. J Neurol Neurosurg Psychiatr 69:519-521
116. Reed MN, Liu P, Kotilinek LA, Ashe KH (2010) Effect size of reference memory deficits in the Morris water maze in Tg2576 mice. Behav Brain Res 212:115-120
117. Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, Norman BA, Baranak CC (2004) Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 62:66-71 (Pubitemid 38082872)
118. Rockwood K, Cosway S, Carver D, Jarrett P, Stadnyk K, Fisk J (1999) The risk of dementia and death after delirium. Age Ageing 28:551-556 (Pubitemid 29535333)
119. Sang N, Zhang J, Marcheselli V, Bazan NG, Chen C (2005) Postsynaptically synthesized prostaglandin E2 (PGE2) modulates hippocampal synaptic transmission via a presynaptic PGE2 EP2 receptor. J Neurosci 25:9858-9870 (Pubitemid 41528023)
120. Shankar GM, Walsh DM (2009) Alzheimer's disease: synaptic dysfunction and abeta. Mol Neurodegener 4:48
121. Sheng JG, Bora SH, Xu G, Borchelt DR, Price DL, Koliatsos VE (2003) Lipopolysaccharide-induced-neuroinflammation increases intracellular accumulation of amyloid precursor protein and amyloid beta peptide in APPswe transgenic mice. Neurobiol Dis 14:133-145 (Pubitemid 37103187)
122. Shi J, Johansson J, Woodling NS, Wang Q, Montine TJ, Andreasson K (2010) The prostaglandin E2 E-prostanoid 4 receptor exerts anti-inflammatory effects in brain innate immunity. J Immunol 184:7207-7218
123. Shie FS, Breyer RM, Montine TJ (2005) Microglia lacking E prostanoid receptor subtype 2 have enhanced abeta phagocytosis yet lack abeta-activated neurotoxicity. Am J Pathol 166:1163-1172 (Pubitemid 40524440)
124. Skelly D, Cunningham C (unpublished data) Synaptic loss and cyclooxygenase 1 activity combine to induce acute exacerbation of dementia
125. Sly LM, Krzesicki RF, Brashler JR, Buhl AE, Mckinley DD, Carter DB, Chin JE (2001) Endogenous brain cytokine mRNA and inflammatory responses to lipopolysaccharide are elevated in the Tg2576 transgenic mouse model of Alzheimer's disease. Brain Res Bull 56:581-588 (Pubitemid 34098810)
126. Soininen H, West C, Robbins J, Niculescu L (2007) Long-term efficacy and safety of celecoxib in Alzheimer's disease. Dement Geriatr Cogn Disord 23:8-21 (Pubitemid 46005786)
127. Stewart S, Cacucci F, Lever C (2011) Which memory task for my mouse? a systematic review of spatial memory performance in the Tg2576 Alzheimer's mouse model. J Alzheimers Dis
128. Sugimoto Y, Narumiya S (2007) Prostaglandin E receptors. J Biol Chem 282:11613-11617 (Pubitemid 47100657)
129. Sung S, Yang H, Uryu K, Lee EB, Zhao L, Shineman D, Trojanowski JQ, Lee VM-Y, Pratico D (2004) Modulation of nuclear factor-{kappa} B activity by indomethacin influences A{beta} levels but not A {beta} precursor protein metabolism in a model of Alzheimer's disease. Am J Pathol 165:2197-2206 (Pubitemid 39578396)
130. Teather LA, Packard MG, Bazan NG (2002) Post-training cyclooxygenase-2 (COX-2) inhibition impairs memory consolidation. Learn Mem 9:41-47 (Pubitemid 34273350)
131. Teeling JL, Cunningham C, Newman TA, Perry VH (2010) The effect of non-steroidal anti-inflammatory agents on behavioural changes and cytokine production following systemic inflammation: implications for a role of COX-1. Brain Behav Immun 24:409-419
132. Terrando N, Rei Fidalgo A, Vizcaychipi M, Cibelli M, Ma D, Monaco C, Feldmann M, Maze M (2010) The impact of IL-1 modulation on the development of lipopolysaccharide-induced cognitive dysfunction. Crit Care 14:R88
133. Terry RD, Masliah E, Salmon DP, Butters N, Deteresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:572-580
134. Tomlinson BE, Irving D, Blessed G (1981) Cell loss in the locus coeruleus in senile dementia of Alzheimer type. J Neurol Sci 49:419-428 (Pubitemid 11184187)
135. Uchikado H, Akiyama H, Kondo H, Ikeda K, Tsuchiya K, Kato M, Oda T, Togo T, Iseki E, Kosaka K (2004) Activation of vascular endothelial cells and perivascular cells by systemic inflammation-an immunohistochemical study of postmortem human brain tissues. Acta Neuropathol 107:341-351 (Pubitemid 38477361)
136. Ushikubi F, Segi E, Sugimoto Y, Murata T, Matsuoka T, Kobayashi T, Hizaki H, Tuboi K, Katsuyama M, Ichikawa A, Tanaka T, Yoshida N, Narumiya S (1998) Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature 395:281-284 (Pubitemid 28447553)
137. Van Munster BC, Korevaar JC, Zwinderman AH, Levi M, Wiersinga WJ, De Rooij SE (2008) Time-course of cytokines during delirium in elderly patients with hip fractures. J Am Geriatr Soc 56:1704-1709
138. Van Munster BC, Bisschop PH, Zwinderman AH, Korevaar JC, Endert E, Wiersinga WJ, Van Oosten HE, Goslings JC, De Rooij SE (2010) Cortisol, interleukins and S100B in delirium in the elderly. Brain Cogn 74:18-23
139. Vermeer SE, Prins ND, Den Heijer T, Hofman A, Koudstaal PJ, Breteler MM (2003) Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 348:1215-1222 (Pubitemid 36359297)
140. Villaran RF, Espinosa-Oliva AM, Sarmiento M, De Pablos RM, Arguelles S, Delgado-Cortes MJ, Sobrino V, Van Rooijen N, Venero JL, Herrera AJ, Cano J, Machado A (2010) Ulcerative colitis exacerbates lipopolysaccharide-induced damage to the nigral dopaminergic system: potential risk factor in Parkinson's disease. J Neurochem 114:1687-1700
141. Vlad SC, Miller DR, Kowall NW, Felson DT (2008) Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 70:1672-1677 (Pubitemid 351644133)
142. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535-539 (Pubitemid 34288854)
143. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414:212-216 (Pubitemid 33051236)
144. Weggen S, Rogers M, Eriksen J (2007) NSAIDs: small molecules for prevention of Alzheimer's disease or precursors for future drug development? Trends Pharmacol Sci 28:536-543 (Pubitemid 47488508)
145. Whitehouse PJ, Price DL, Clark AW, Coyle JT, Delong MR (1981) Alzheimer disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol 10:122-126 (Pubitemid 11053099)
146. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR (1982) Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 215:1237-1239 (Pubitemid 12106486)
147. WHO (1992) The ICD-10 classification of mental and behavioural disorders. Diagnostic criteria for research.World Health Organisation, Geneva
148. Wirths O, Bayer TA (2010) Neuron loss in transgenic mouse models of Alzheimer's disease. Int J Alzheimers Dis. doi:10.4061/2010/ 723782
149. Yan Q, Zhang J, Liu H, Babu-Khan S, Vassar R, Biere AL, Citron M, Landreth G (2003) Anti-inflammatory drug therapy alters betaamyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 23:7504-7509 (Pubitemid 37034066)
150. Yasojima K, Schwab C, Mcgeer EG, Mcgeer PL (1999) Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res 830:226-236 (Pubitemid 29297950)
151. Yermakova AV, Rollins J, Callahan LM, Rogers J, O'banion MK (1999) Cyclooxygenase-1 in human Alzheimer and control brain: quantitative analysis of expression by microglia and CA3 hippocampal neurons. J Neuropathol Exp Neurol 58:1135-1146 (Pubitemid 29519837)